Low tumor glutathione level as a sensitivity marker for glutamate‑cysteine ligase inhibitors

Nishizawa,Satoru; Araki,Hideo; Ishikawa,Yoshinori; Kitazawa,Satoshi; Hata,Akito; Soga,Tomoyoshi; Hara,Takahito

doi:10.3892/ol.2018.8447

Low tumor glutathione level as a sensitivity marker for glutamate‑cysteine ligase inhibitors

Authors:
- Satoru Nishizawa
- Hideo Araki
- Yoshinori Ishikawa
- Satoshi Kitazawa
- Akito Hata
- Tomoyoshi Soga
- Takahito Hara
View Affiliations

Affiliations: Oncology Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251‑8555, Japan, Biomolecular Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251‑8555, Japan, Institute for Advanced Bioscience, Keio University, Tsuruoka, Yamagata 997‑0052, Japan
Published online on: April 10, 2018 https://doi.org/10.3892/ol.2018.8447
Pages: 8735-8743

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous metabolomic analyses of cancer have revealed elevated glutathione levels in tumors. An inhibitor of cystine uptake was identified to suppress glutathione biosynthesis, leading to ferroptosis, a novel iron‑dependent form of cell death that differs from apoptosis and necrosis. Glutamate‑cysteine ligase (GCL) is the rate‑limiting enzyme in the glutathione biosynthesis pathway. Buthionine sulfoximine (BSO), a GCL inhibitor, has previously demonstrated limited clinical benefits. Therefore, selecting patients who respond well to the inhibitor is a key approach for successful future drug development. Ferroptosis induction by BSO has not been fully examined in prior studies. Therefore, the present study investigated the pharmacological effects of BSO and the association between basal intracellular glutathione levels and sensitivity to BSO in cultured cell lines derived from various types of cancer, including those of the kidney [769P, 786‑O, A‑498, A704, ACHN, Caki‑1, Caki‑2, G401, G402, RCC4 VHL(‑/‑), RCC4 VHL(+/+), SK‑NEP‑1 and SW156] and ovaries (A2780 and A2780/CDDP). BSO was demonstrated to suppress glutathione levels and induce lipid peroxidation, thereby inhibiting cell viability. The viability‑reducing effects of BSO were attenuated by ferroptosis inhibition and enhanced by iron, indicating that BSO induced ferroptosis in cancer cells. The cell lines sensitive to BSO, including G402, tended to exhibit non‑significantly lower levels of glutathione compared with the BSO‑insensitive cell lines, including Caki‑2 (P=0.08). Patient sample data indicated the existence of a population of colorectal tumors with lower glutathione levels compared with those of matched normal tissues that might be suitable for the clinical testing of sensitivity to GCLC inhibitors. Collectively, these data suggest that GCL inhibition leads to ferroptosis in cancer cells, and that low glutathione tumor levels may be a patient selection marker for the use of GCL inhibitors in the treatment of tumors.

View Figures

View References

1	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
2	Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
3	Cairns RA, Harris IS and Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95. 2011. View Article : Google Scholar : PubMed/NCBI
4	Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, Aksoy BA, Liu EM, Shen R, Lee W, et al: An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell. 29:104–116. 2016. View Article : Google Scholar : PubMed/NCBI
5	Denkert C, Budczies J, Weichert W, Wohlgemuth G, Scholz M, Kind T, Niesporek S, Noske A, Buckendahl A, Dietel M and Fiehn O: Metabolite profiling of human colon carcinoma-deregulation of TCA cycle and amino acid turnover. Mol Cancer. 7:722008. View Article : Google Scholar : PubMed/NCBI
6	Wang H, Wang L, Zhang H, Deng P, Chen J, Zhou B, Hu J, Zou J, Lu W, Xiang P, et al: ¹H NMR-based metabolic profiling of human rectal cancer tissue. Mol Cancer. 12:1212013. View Article : Google Scholar : PubMed/NCBI
7	Li B, Qiu B, Lee DS, Walton ZE, Ochocki JD, Mathew LK, Mancuso A, Gade TP, Keith B, Nissim I and Simon MC: Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature. 513:251–255. 2014. View Article : Google Scholar : PubMed/NCBI
8	Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al: Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
9	Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, et al: Regulation of ferroptotic cancer cell death by GPX4. Cell. 156:317–331. 2014. View Article : Google Scholar : PubMed/NCBI
10	Yang WS and Stockwell BR: Ferroptosis: Death by lipid peroxidation. Trends Cell Biol. 26:165–176. 2016. View Article : Google Scholar : PubMed/NCBI
11	Skouta R, Dixon SJ, Wang J, Dunn DE, Orman M, Shimada K, Rosenberg PA, Lo DC, Weinberg JM, Linkermann A and Stockwell BR: Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc. 136:4551–4556. 2014. View Article : Google Scholar : PubMed/NCBI
12	Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, Kang R and Tang D: Ferroptosis: Process and function. Cell Death Differ. 23:369–379. 2016. View Article : Google Scholar : PubMed/NCBI
13	Lu SC: Glutathione synthesis. Biochim Biophys Acta. 1830:3143–3153. 2013. View Article : Google Scholar : PubMed/NCBI
14	Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT and Wilding G: Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst. 89:1789–1796. 1997. View Article : Google Scholar : PubMed/NCBI
15	Sakamoto K, Adachi Y, Komoike Y, Kamada Y, Koyama R, Fukuda Y, Kadotani A, Asami T and Sakamoto JI: Novel DOCK2-selective inhibitory peptide that suppresses B-cell line migration. Biochem Biophys Res Commun. 483:183–190. 2017. View Article : Google Scholar : PubMed/NCBI
16	Winterbourn CC and Brennan SO: Characterization of the oxidation products of the reaction between reduced glutathione and hypochlorous acid. Biochem J. 326:87–92. 1997. View Article : Google Scholar : PubMed/NCBI
17	Winkler BS, DeSantis N and Solomon F: Multiple NADPH-producing pathways control glutathione (GSH) content in retina. Exp Eye Res. 43:829–847. 1986. View Article : Google Scholar : PubMed/NCBI
18	Patra KC and Hay N: The pentose phosphate pathway and cancer. Trends Biochem Sci. 39:347–354. 2014. View Article : Google Scholar : PubMed/NCBI
19	Muñoz-Pinedo C, El Mjiyad N and Ricci JE: Cancer metabolism: Current perspectives and future directions. Cell Death Dis. 3:e2482012. View Article : Google Scholar : PubMed/NCBI
20	Singh D, Arora R, Kaur P, Singh B, Mannan R and Arora S: Overexpression of hypoxia-inducible factor and metabolic pathways: Possible targets of cancer. Cell Biosci. 7:622017. View Article : Google Scholar : PubMed/NCBI
21	Courtnay R, Ngo DC, Malik N, Ververis K, Tortorella SM and Karagiannis TC: Cancer metabolism and the Warburg effect: The role of HIF-1 and PI3K. Mol Biol Rep. 42:841–851. 2015. View Article : Google Scholar : PubMed/NCBI
22	Haase VH: The VHL tumor suppressor: Master regulator of HIF. Curr Pharm Des. 15:3895–3903. 2009. View Article : Google Scholar : PubMed/NCBI
23	Satoh K, Yachida S, Sugimoto M, Oshima M, Nakagawa T, Akamoto S, Tabata S, Saitoh K, Kato K, Sato S, et al: Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC. Proc Natl Acad Sci USA. 114:E7697–E7706. 2017. View Article : Google Scholar : PubMed/NCBI
24	Yuan M, Breitkopf SB, Yang X and Asara JM: A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat Protoc. 7:872–881. 2012. View Article : Google Scholar : PubMed/NCBI
25	Soga T and Heiger DN: Amino acid analysis by capillary electrophoresis electrospray ionization mass spectrometry. Anal Chem. 72:1236–1241. 2000. View Article : Google Scholar : PubMed/NCBI
26	Soga T, Ohashi Y, Ueno Y, Naraoka H, Tomita M and Nishioka T: Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J Proteome Res. 2:488–494. 2003. View Article : Google Scholar : PubMed/NCBI
27	Soga T, Igarashi K, Ito C, Mizobuchi K, Zimmermann HP and Tomita M: Metabolomic profiling of anionic metabolites by capillary electrophoresis mass spectrometry. Anal Chem. 81:6165–6174. 2009. View Article : Google Scholar : PubMed/NCBI
28	Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M and Spriggs DR: Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: An attempt at modulation of glutathione. J Clin Oncol. 12:194–205. 1994. View Article : Google Scholar : PubMed/NCBI
29	Mehta S, Shelling A, Muthukaruppan A, Lasham A, Blenkiron C, Laking G and Print C: Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol. 2:125–148. 2010. View Article : Google Scholar : PubMed/NCBI
30	Dienstmann R, Rodon J and Tabernero J: Biomarker-driven patient selection for early clinical trials. Curr Opin Oncol. 25:305–312. 2013.PubMed/NCBI
31	Schmidt KT, Chau CH, Price DK and Figg WD: Precision oncology medicine: The clinical relevance of patient-specific biomarkers used to optimize cancer treatment. J Clin Pharmacol. 56:1484–1499. 2016. View Article : Google Scholar : PubMed/NCBI
32	Terpstra M, Vaughan TJ, Ugurbil K, Lim KO, Schulz SC and Gruetter R: Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: Application to schizophrenia. MAGMA. 18:276–282. 2005. View Article : Google Scholar : PubMed/NCBI